Abstract 2287: Bispecific anti-PD1 checkpoint inhibitors antibodies (BiCKI), an optimized platform designed to tackle anti-PD-(L)1 primary and secondary resistance mechanisms

Authors: Caroline Mary, Aurore Morello, Virginie Thepenier, Géraldine Teppaz, Justine Durand, Nicolas Poirier

Published: 2020-09-04

DOI: 10.1158/1538-7445.am2020-2287

Source: Full article